STOCK TITAN

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Nektar Therapeutics (NKTR) has agreed to sell its Huntsville, Alabama manufacturing facility and PEGylation reagent supply business to Ampersand Capital Partners for $90 million, consisting of $70 million in cash and $20 million in equity ownership in the new portfolio company. The 124,000-square-foot facility will become a standalone company under Ampersand, with all current employees being offered positions. The strategic sale allows Nektar to streamline operations and focus on immunology R&D programs while extending its cash runway into Q4 2026. The deal includes supply agreements for Nektar's PEG reagent needs and is expected to close by December 2, 2024.

Nektar Therapeutics (NKTR) ha accettato di vendere il suo stabilimento di produzione a Huntsville, Alabama, e il business dei reagenti PEGilati a Ampersand Capital Partners per 90 milioni di dollari, di cui 70 milioni in contante e 20 milioni in partecipazione azionaria nella nuova azienda del portafoglio. La struttura di 124.000 piedi quadrati diventerà una società autonoma sotto Ampersand, con tutti i dipendenti attuali che riceveranno un'offerta di lavoro. Questa vendita strategica consente a Nektar di snellire le operazioni e concentrarsi sui programmi di ricerca e sviluppo in immunologia, estendendo così il proprio margine di liquidità fino al quarto trimestre del 2026. L'accordo include contratti di fornitura per le necessità di reagenti PEG di Nektar e si prevede che si chiuda entro il 2 dicembre 2024.

Nektar Therapeutics (NKTR) ha acordado vender su instalación de fabricación en Huntsville, Alabama, y su negocio de suministro de reactivos de PEGilación a Ampersand Capital Partners por 90 millones de dólares, que consiste en 70 millones en efectivo y 20 millones en participación accionaria en la nueva empresa del portafolio. La instalación de 124,000 pies cuadrados se convertirá en una empresa independiente bajo Ampersand, con todas las posiciones actuales ofrecidas a los empleados. La venta estratégica permite a Nektar optimizar sus operaciones y centrarse en los programas de I+D en inmunología, mientras extiende su liquidez hasta el cuarto trimestre de 2026. El acuerdo incluye contratos de suministro para las necesidades de reactivos PEG de Nektar y se espera que se cierre antes del 2 de diciembre de 2024.

Nektar Therapeutics (NKTR)는 앨라배마주 헌츠빌에 있는 제조 시설과 PEG화 시약 공급 사업을 Ampersand Capital Partners에 9천만 달러에 판매하기로 합의했습니다. 이 금액은 현금 7천만 달러와 새로운 포트폴리오 회사의 주식 2천만 달러로 구성됩니다. 124,000 평방 피트의 시설은 Ampersand의 독립적인 회사가 되며, 모든 현재 직원들에게는 직위가 제공됩니다. 이 전략적 판매는 Nektar가 운영을 간소화하고 면역학 연구 개발 프로그램에 집중하며, 2026년 4분기까지 현금 여유를 늘릴 수 있게 합니다. 이 거래에는 Nektar의 PEG 시약 공급 계약이 포함되며, 2024년 12월 2일 이전에 마감될 것으로 예상됩니다.

Nektar Therapeutics (NKTR) a accepté de vendre son installation de fabrication à Huntsville, Alabama, ainsi que son activité de fourniture de réactifs de PEGylation à Ampersand Capital Partners pour un montant de 90 millions de dollars, dont 70 millions en espèces et 20 millions en participation dans la nouvelle société du portefeuille. L'installation de 124 000 pieds carrés deviendra une société autonome sous Ampersand, avec des postes offerts à tous les employés actuels. Cette vente stratégique permet à Nektar de rationaliser ses opérations et de se concentrer sur les programmes de R&D en immunologie, tout en prolongant sa trésorerie jusqu'au quatrième trimestre 2026. L'accord comprend des contrats d'approvisionnement pour les besoins en réactifs PEG de Nektar et devrait être finalisé d'ici le 2 décembre 2024.

Nektar Therapeutics (NKTR) hat zugestimmt, seine Produktionsstätte in Huntsville, Alabama, sowie sein Liefergeschäft für PEGylierungsreagenzien für 90 Millionen Dollar an Ampersand Capital Partners zu verkaufen, bestehend aus 70 Millionen Dollar in bar und 20 Millionen Dollar in Eigenkapitalbeteiligung an dem neuen Portfolio-Unternehmen. Die 124.000 Quadratfuß große Anlage wird eine eigenständige Gesellschaft unter Ampersand, wobei alle derzeitigen Mitarbeiter Stellen angeboten bekommen. Der strategische Verkauf ermöglicht es Nektar, die Abläufe zu optimieren und sich auf F&E-Programme in der Immunologie zu konzentrieren, während der Cashflow bis ins vierte Quartal 2026 verlängert wird. Die Vereinbarung umfasst Lieferverträge für Nektars PEG-Reagenzbedarf und soll bis zum 2. Dezember 2024 abgeschlossen sein.

Positive
  • Receives $90 million total consideration ($70M cash + $20M equity)
  • Extends cash runway into Q4 2026
  • Retains all rights to current and future royalty streams from existing PEGylated product licenses
  • Maintains access to PEGylation reagents through supply agreements
Negative
  • Divestiture of revenue-generating manufacturing facility
  • Reduction in operational capabilities and assets

Insights

This strategic divestiture significantly strengthens Nektar's financial position with an immediate $70M cash injection and $20M in equity retention. The deal extends the company's cash runway into Q4 2026, providing important operational flexibility. The transaction structure is particularly advantageous, combining upfront liquidity with potential upside through the retained equity stake and board representation in the new entity.

Most importantly, Nektar maintains all rights to existing PEGylation product royalties and milestones while securing guaranteed supply agreements for its pipeline programs. This clean separation allows the company to streamline operations while preserving key revenue streams and ensuring manufacturing continuity for critical programs like rezpegaldesleukin.

The $90M total consideration represents a significant portion of Nektar's current market cap of $224M, indicating this is a material transaction that optimizes asset utilization while maintaining strategic optionality.

The Huntsville facility's transition to Ampersand's portfolio represents a strategic optimization of specialized manufacturing assets. The 124,000 square foot facility's established commercial-scale supply chain contracts with major pharmaceutical companies make it an attractive standalone business. Ampersand's commitment to additional growth capital investment suggests potential expansion of manufacturing capabilities and client base.

The retention of all employees and establishment of dedicated supply agreements ensures operational continuity for both existing customers and Nektar's development programs. This structure maintains the facility's specialized PEGylation expertise while potentially allowing for increased capacity utilization under focused management.

Huntsville-based facility to be spun out as standalone Ampersand portfolio company.

Nektar to receive $90 million in total consideration for the business, comprised of $70 million in cash and $20 million equity ownership in new portfolio company.

Strategic divestiture allows Nektar to streamline its operations and continue its strategic focus on the development of core R&D programs in immunology.

SAN FRANCISCO, Nov. 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and reagent supply business to Ampersand Capital Partners, a Boston-based private equity firm with a decades-long track record of investing in life sciences and healthcare companies, including contract manufacturing and pharma services businesses.

Ampersand has agreed to acquire Nektar's commercial-scale manufacturing facility and PEGylation reagent supply business for a total consideration of $90 million, comprised of $70 million in cash proceeds and $20 million in a retained equity position for Nektar in a newly-created Ampersand portfolio company. Ampersand has also committed to invest additional growth equity capital into the new portfolio company. Following the closing of the transaction, Nektar will be entitled to appoint a representative to the board of the new Ampersand portfolio company.

The Huntsville site is a 124,000 square foot, commercial-scale specialized manufacturing facility with a strong history of supporting commercial supply chains for PEGylated therapeutics across global markets. The facility has several commercial-scale supply chain contracts with leading pharmaceutical companies. All of Nektar's employees at the Huntsville facility will be offered employment at the new portfolio company, ensuring continuity in the high-quality manufacturing and PEGylation expertise that longstanding customers trust and rely on.

"This sale streamlines Nektar's operations as we continue to focus on the future success and clinical advancement of rezpegaldesleukin and our other antibody-based immunology pipeline assets, including our TNFR2 antibody and bispecific programs," said Howard W. Robin, President and CEO of Nektar Therapeutics.  "We believe Ampersand is an optimal partner to lead the manufacturing activities at the Huntsville facility. Importantly, Ampersand's commitment to investing in the plant's business will help ensure that Nektar's existing commercial customers of PEGylation reagents will continue to be well served and will also provide uninterrupted access to a reliable supply of PEGylation reagents for Nektar's needs. The sale also further extends Nektar's cash runway into the fourth quarter of 2026."

Nektar and the new Ampersand portfolio company will be entering into manufacturing supply agreements to meet Nektar's PEG reagent needs for rezpegaldesleukin and certain pipeline programs.

"We were immediately impressed with the world-class PEGylation reagent manufacturing capabilities at this facility," said David Anderson, General Partner, Ampersand Capital Partners. "The Huntsville site and its employees have played an important role in the development of significant FDA-approved PEGylated therapeutic medicines. We look forward to investing in and growing the site as a stand-alone manufacturing business dedicated to serving existing and new customers." 

The sale is not subject to financing contingencies. The transaction will be subject to customary closing conditions and costs and is expected to close by December 2, 2024. Following the closing, Nektar will retain all rights to current and future royalty streams and milestones related to existing PEGylated product license agreements.

UBS Investment Bank acted as exclusive financial advisor and Sidley Austin LLP served as legal advisor to Nektar Therapeutics. Goodwin Procter LLP acted as legal advisor to Ampersand Capital Partners.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

About Ampersand Capital Partners

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit ampersandcapital.com or follow us on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements which can be identified by words such as: "will," "expect," "develop," "extend," "advance," "anticipate," "can," and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding the therapeutic potential of, and future development plans for rezpegaldesleukin, NKTR-0165, and our other drug candidates, and whether all the closing conditions of the announced definitive agreement will be met. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of rezpegaldesleukin, NKTR-0165, and our other drug candidates are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, and our other drug candidates are investigational agents and continued research and development for these drug candidates is subject to substantial risks, including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii)  rezpegaldesleukin, NKTR-0165, and our other drug candidates are in preclinical and clinical development, and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv) the timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (v) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vi) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2024. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact: 

For Investors:
Vivian Wu
Nektar Therapeutics
628-895-0661

For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-announces-definitive-agreement-with-ampersand-capital-partners-to-sell-its-commercial-pegylation-reagent-manufacturing-business-in-alabama-302295051.html

SOURCE Nektar Therapeutics

FAQ

How much is Nektar (NKTR) selling its Alabama manufacturing facility for?

Nektar is selling its Alabama manufacturing facility for $90 million total consideration, comprising $70 million in cash and $20 million in equity ownership in the new Ampersand portfolio company.

When will Nektar's (NKTR) sale of the Huntsville facility close?

The sale is expected to close by December 2, 2024, subject to customary closing conditions.

What happens to Nektar's (NKTR) cash runway after the facility sale?

The sale extends Nektar's cash runway into the fourth quarter of 2026.

Will Nektar (NKTR) retain access to PEGylation reagents after the sale?

Yes, Nektar will maintain access through manufacturing supply agreements with the new Ampersand portfolio company for its PEG reagent needs.

Nektar Therapeutics

NASDAQ:NKTR

NKTR Rankings

NKTR Latest News

NKTR Stock Data

188.15M
182.51M
1.06%
76.69%
2.84%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO